Pyxis Oncology (PYXS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.68, -6.67% vs the prior close of $1.80.
- Volume 908.23K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PYXS slides 6.7% to $1.68, a 3-month low. Closed at $1.68, -6.67% vs the prior close of $1.80. Day range $1.66–$1.79, opened at $1.79.
PYXS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PYXS slides 6.7% to $1.68, a 3-month low
- Closed at $1.68, -6.67% vs the prior close of $1.80. Day range $1.66–$1.79, opened at $1.79.
- Volume was 908.23K shares, 0.7x its 50-day average of 1.33M.
- Price is -42.8% vs its 50-day average ($2.94) and -21.7% vs its 200-day average ($2.15).
- 52-week range $1.03–$5.55; today's close sits at 14% of that range, 69.7% below the 52-week high.
Oct 15, 2026 — PYXS rises 0.6% to $1.80
- Closed at $1.80, +0.56% vs the prior close of $1.79. Day range $1.75–$1.84, opened at $1.79.
- Volume was 545.70K shares, 0.4x its 50-day average of 1.34M — lighter than usual.
- Price is -39.6% vs its 50-day average ($2.98) and -16.0% vs its 200-day average ($2.14).
- 52-week range $1.03–$5.55; today's close sits at 17% of that range, 67.6% below the 52-week high.
Oct 14, 2026 — PYXS slides 3.2% to $1.79, a 3-month low, 3 down days in a row
- Closed at $1.79, -3.24% vs the prior close of $1.85. Day range $1.74–$1.88, opened at $1.82.
- Volume was 1.56M shares, 1.2x its 50-day average of 1.32M.
- Price is -40.5% vs its 50-day average ($3.01) and -16.3% vs its 200-day average ($2.14).
- 52-week range $1.03–$5.55; today's close sits at 17% of that range, 67.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PYXS slides 8.0% to $1.85, a 3-month low
- Closed at $1.85, -7.96% vs the prior close of $2.01. Day range $1.85–$2.00, opened at $1.99.
- Volume was 900.40K shares, 0.7x its 50-day average of 1.33M.
- Price is -39.0% vs its 50-day average ($3.04) and -13.4% vs its 200-day average ($2.14).
- 52-week range $1.03–$5.55; today's close sits at 18% of that range, 66.7% below the 52-week high.
Oct 12, 2026 — PYXS dips 1.0% to $2.01
- Closed at $2.01, -0.99% vs the prior close of $2.03. Day range $1.99–$2.08, opened at $2.03.
- Volume was 505.70K shares, 0.4x its 50-day average of 1.33M — lighter than usual.
- Price is -34.3% vs its 50-day average ($3.06) and -5.7% vs its 200-day average ($2.13).
- 52-week range $1.03–$5.55; today's close sits at 22% of that range, 63.8% below the 52-week high.
Oct 9, 2026 — PYXS rises 2.0% to $2.03
- Closed at $2.03, +2.01% vs the prior close of $1.99. Day range $1.98–$2.06, opened at $1.99.
- Volume was 950.40K shares, 0.7x its 50-day average of 1.33M.
- Price is -33.9% vs its 50-day average ($3.07) and -4.5% vs its 200-day average ($2.13).
- 52-week range $1.03–$5.55; today's close sits at 22% of that range, 63.4% below the 52-week high.
Oct 8, 2026 — PYXS dips 1.0% to $1.99, a 3-month low, 3 down days in a row
- Closed at $1.99, -1.00% vs the prior close of $2.01. Day range $1.90–$2.03, opened at $2.03.
- Volume was 1.10M shares, 0.8x its 50-day average of 1.32M.
- Price is -35.6% vs its 50-day average ($3.09) and -6.2% vs its 200-day average ($2.12).
- 52-week range $1.03–$5.55; today's close sits at 21% of that range, 64.1% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — PYXS dips 0.5% to $2.01, a 3-month low
- Closed at $2.01, -0.50% vs the prior close of $2.02. Day range $2.00–$2.09, opened at $2.02.
- Volume was 957.80K shares, 0.7x its 50-day average of 1.34M.
- Price is -35.3% vs its 50-day average ($3.11) and -5.1% vs its 200-day average ($2.12).
- 52-week range $1.03–$5.55; today's close sits at 22% of that range, 63.8% below the 52-week high.
Oct 6, 2026 — PYXS slides 9.8% to $2.02, a 3-month low
- Closed at $2.02, -9.82% vs the prior close of $2.24. Day range $2.00–$2.22, opened at $2.22.
- Volume was 1.40M shares, 1.1x its 50-day average of 1.33M.
- Price is -35.4% vs its 50-day average ($3.13) and -4.6% vs its 200-day average ($2.12).
- 52-week range $1.03–$5.55; today's close sits at 22% of that range, 63.6% below the 52-week high.
Oct 5, 2026 — PYXS jumps 4.7% to $2.24
- Closed at $2.24, +4.67% vs the prior close of $2.14. Day range $2.05–$2.26, opened at $2.12.
- Volume was 1.52M shares, 1.1x its 50-day average of 1.32M.
- Price is -28.7% vs its 50-day average ($3.14) and +5.4% vs its 200-day average ($2.12).
- 52-week range $1.03–$5.55; today's close sits at 27% of that range, 59.6% below the 52-week high.
Oct 2, 2026 — PYXS dips 2.3% to $2.14, a 3-month low, 4 down days in a row
- Closed at $2.14, -2.28% vs the prior close of $2.19. Day range $2.10–$2.31, opened at $2.21.
- Volume was 2.00M shares, 1.5x its 50-day average of 1.31M.
- Price is -32.1% vs its 50-day average ($3.15) and +0.3% vs its 200-day average ($2.13).
- 52-week range $1.03–$5.55; today's close sits at 25% of that range, 61.4% below the 52-week high.
- That makes 4 straight losses.
PYXS latest news & SEC filings
Every SEC filing by or about PYXS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Oct 9, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 9, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 5, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gordonmd Global Investments Lp & Gordonmd Long Biased Master Fund Lp & Gordonmd Long Biased Gp Llc & Gordon Craig D bought 5,517,000 shares on Oct 1, 2026; now holds 15,541,909
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Oct 1, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 29, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 29, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 28, 2026 · Form 424B2 — Prospectus for a securities offering
Prospectus for a securities offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 27, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Things to know before you trade PYXS
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 23, 2026, Nov 3, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.58% (largest 19.7%). That is a volatile stock.
- Liquidity: about 1.34M shares (≈$2.25M) trade per day on average.
- 52-week position: $1.68 vs a range of $1.03–$5.55 (14% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 16 sales; latest: Jakob Dupont sold 35,000 shares on Jun 30, 2026.
- Latest filings: 8-K Oct 1, 2026; 8-K Sep 9, 2026; 8-K Sep 8, 2026.
- Share count: 83.41M shares outstanding (Aug 12, 2026), +34.5% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PYXS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.79 | 1.79 | 1.66 | 1.68 | 908.23K |
| Oct 15, 2026 | 1.79 | 1.84 | 1.75 | 1.80 | 545.70K |
| Oct 14, 2026 | 1.82 | 1.88 | 1.74 | 1.79 | 1.56M |
| Oct 13, 2026 | 1.99 | 2.00 | 1.85 | 1.85 | 900.40K |
| Oct 12, 2026 | 2.03 | 2.08 | 1.99 | 2.01 | 505.70K |
| Oct 9, 2026 | 1.99 | 2.06 | 1.98 | 2.03 | 950.40K |
| Oct 8, 2026 | 2.03 | 2.03 | 1.90 | 1.99 | 1.10M |
| Oct 7, 2026 | 2.02 | 2.09 | 2.00 | 2.01 | 957.80K |
| Oct 6, 2026 | 2.22 | 2.22 | 2.00 | 2.02 | 1.40M |
| Oct 5, 2026 | 2.12 | 2.26 | 2.05 | 2.24 | 1.52M |
| Oct 2, 2026 | 2.21 | 2.31 | 2.10 | 2.14 | 2.00M |
| Oct 1, 2026 | 2.31 | 2.31 | 2.19 | 2.19 | 2.60M |
| Sep 30, 2026 | 2.38 | 2.41 | 2.12 | 2.33 | 8.15M |
| Sep 29, 2026 | 2.94 | 2.94 | 2.83 | 2.90 | 335.50K |
| Sep 28, 2026 | 2.81 | 2.91 | 2.75 | 2.90 | 368.10K |
| Sep 25, 2026 | 2.91 | 2.92 | 2.79 | 2.86 | 609.70K |
| Sep 24, 2026 | 3.22 | 3.25 | 2.86 | 2.92 | 875.30K |
| Sep 23, 2026 | 3.36 | 3.36 | 3.20 | 3.22 | 433.60K |
| Sep 22, 2026 | 3.21 | 3.40 | 3.19 | 3.36 | 479.80K |
| Sep 21, 2026 | 3.38 | 3.38 | 3.19 | 3.19 | 632.80K |
About Pyxis Oncology
Pyxis Oncology (PYXS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1782223.
PYXS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Thomas Civik | CEO & Chairman of the Board | Sep 8, 2026 |
| Darren S Cline | Director | Mar 25, 2026 |
| Jakob Dupont | Director | Aug 20, 2026 |
| John L Flavin | Director | Mar 25, 2026 |
| Rachel Humphrey | Director | Mar 25, 2026 |
| Freda C Lewis-Hall | Director | Mar 25, 2026 |
| Michael A Metzger | Director | Mar 25, 2026 |
| Santhosh Palani | Director | Mar 25, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Thomas Civik | CEO & Chairman of the Board | Sep 8, 2026 |
| Jitendra Wadhane | Prin Fin & Acct Officer | Mar 25, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 30, 2026 | Jakob Dupont | Sale | 35,000 | $3.06 |
| Jun 30, 2026 | Jakob Dupont | Sale | 35,000 | $3.06 |
| Jun 30, 2026 | Jakob Dupont | Sale | 35,000 | $3.06 |
| Jun 30, 2026 | Jakob Dupont | Sale | 35,000 | $3.06 |
| Apr 21, 2025 | Rachel Humphrey | Sale | 13,896 | $1.03 |
| Apr 21, 2025 | Rachel Humphrey | Sale | 13,896 | $1.03 |
| Apr 21, 2025 | Rachel Humphrey | Sale | 13,896 | $1.03 |
| Apr 21, 2025 | Rachel Humphrey | Sale | 13,896 | $1.03 |
| Apr 17, 2025 | Rachel Humphrey | Sale | 200 | $0.97 |
| Apr 17, 2025 | Rachel Humphrey | Sale | 200 | $0.97 |
| Apr 17, 2025 | Rachel Humphrey | Sale | 200 | $0.97 |
| Apr 17, 2025 | Rachel Humphrey | Sale | 200 | $0.97 |
| Apr 14, 2025 | Rachel Humphrey | Sale | 1,400 | $0.97 |
| Apr 14, 2025 | Rachel Humphrey | Sale | 1,400 | $0.97 |
| Apr 14, 2025 | Rachel Humphrey | Sale | 1,400 | $0.97 |
PYXS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $13.86M | $-79.62M | -1.28 | $-63.50M |
| Dec 31, 2024 | $16.15M | $-77.33M | -1.32 | $-57.67M |
| Dec 31, 2023 | — | $-73.79M | -1.85 | $-70.71M |
| Dec 31, 2022 | — | $-120.72M | -3.65 | $-89.33M |
| Dec 31, 2021 | — | $-75.97M | -8.95 | $-35.33M |
Latest balance sheet: total assets $54.92M, total liabilities $43.48M, cash $18.86M (as of Jun 30, 2026).
PYXS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $3.01 |
| May 14, 2026 | 8-K Item 2.02 (results) | $2.21 |
| Mar 23, 2026 | 8-K Item 2.02 (results) | $1.42 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $3.81 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $1.13 |
| May 15, 2025 | 8-K Item 2.02 (results) | $1.11 |
| Mar 18, 2025 | 8-K Item 2.02 (results) | $1.06 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $4.62 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 21, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PYXS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.